- NeuroQuant® Brain Tumor
FDA-cleared software for advanced brain tumor analyses
Powered by AI and advanced diffusion MRI, NeuroQuant® Brain Tumor assists radiologists, oncologists, and the Tumor Board by providing objective quantification and analysis of tumor changes over time.
Automated Brain Tumor Segmentation
NeuroQuant® Brain Tumor includes tumor segmentations that are color-coded slice by slice and routed to PACS, making it easy for radiologists to identify regions of interest and track changes over time. The integration of Restriction Spectrum Imaging (RSI) provides deeper insights into tumor microstructure, enhancing the analysis with more detailed information than traditional imaging methods.
Benefits
High- and low-grade glioma
Slice by slice tumor segmentation in DICOM format
Longitudinal disease assessment
Automated quantification and tracking of pre- and post-treatment brain tumor volumes across time
Clinical trial support
Objective tumor quantification for improved confidence and efficiency
Unique microstructure insights
Patented Restriction Spectrum Imaging (RSI) advanced diffusion technology
NeuroQuant Brain Tumor report
Comprehensive segmentation and volumetrics reporting, automatically routed to PACS.
The NeuroQuant® Brain Tumor Report
Provides tumor boards with a time series of brain tumor volume analysis across scans. 3D volumetrics are displayed for tumor ROIs that enable more efficient and objective reviews.
